Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment

DISEASE CHARACTERISTICS:

* Histologically confirmed malignant solid tumor

  * Advanced or unresectable disease
* No standard therapeutic option available
* Evaluable disease (according to RECIST criteria) that has not been previously irradiated

  * Prior radiotherapy to the marker lesion(s) allowed provided there is evidence of progression since radiotherapy
* Brain metastases allowed provided the following criteria are met:

  * CNS-directed treatment was given and was completed \> 3 months ago
  * CNS disease has been clinically and radiographically stable for ≥ 8 weeks

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Absolute neutrophil count ≥ 1,500/µL
* Platelet count ≥ 100,000/µL
* Creatinine clearance ≥ 60 mL/min
* Total bilirubin ≤ 1.2 mg/dL
* Transaminases ≤ 5 times upper limit of normal (ULN)
* Magnesium ≥ lower limit of normal
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 24 weeks (females) or for 4 weeks (males) after completion of study therapy
* Willing to avoid pregnancy for 3 months after completion of study therapy
* No neuropathy ≥ grade 2
* No concurrent life-threatening acute medical illness
* No impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
* No active bleeding diathesis

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* At least 3 weeks since prior major surgery, radiotherapy (including radiotherapy involving the abdomen or spine), chemotherapy, or other systemic anticancer therapy and recovered
* At least 4 weeks since prior investigational drugs
* No concurrent CYP3A4 inducers or inhibitors that cannot be substituted by a different agent
* No concurrent oral anti-vitamin K medication (except for low-dose warfarin)
* No concurrent colony stimulating factors during the first course of treatment